© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to July
CNS-penetrant tubulin-binder (colchicine site)
oral agent in Ph. I for leiomyosarcoma
not a P-gp substrate, formerly BMI-1 inh.
Molecular Cancer Therapeutics
PTC Therapeutics, South Plainfield, US
The PTC Therapeutics oral, brain-penetrant tubulin-binding agent, PTC596, is in Ph. I clinical studies for advanced solid tumors (starting dose of 200 mg PO BIW). We recently highlighted encequidar, a P-gp…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.